

**REMARKS**

Applicants request entry of the claim amendments herein under Rule 116, given that they address issues raised for the first time in the final Office Action. In particular, the objection under 37 CFR 1.75(c) is a new rejection, and the 112, first paragraph rejection of claims 34 and 35 is also newly raised.

**Objection under 37 CFR 1.75(c)**

Claim 21 is objected to as being of improper dependent form for failing to further limit the subject matter of the previous claim.

Applicants traverse the rejection on the basis that claim 21 refers to the "initial dose" which can comprise a plurality of doses. Notwithstanding this, Applicants have canceled this claim in the interests of expediting prosecution, thus mooted the objection.

**Section 112, first paragraph**

Claims 34 and 36 are rejected under 35 USC Section 112, first paragraph with respect to the term "anthracycline derivative" therein (Applicants believe claims 34 and 35 are intended). Applicants have addressed this rejection by replacing the term "anthracycline derivative" in claims 34 and 35 with the term "anthracycline" which the Office indicates is described (Office Action, page 6, line 14). Also, the typographical error as to the spelling of anthracycline in claim 34 is corrected herein. Reconsideration and withdrawal of the rejection is respectfully requested.

Respectfully submitted,  
GENENTECH, INC.

Date: October 4, 2007

By: /Wendy M. Lee/  
Wendy M. Lee  
Reg. No. 40,378  
Telephone: (650) 225-1994